Pitcairn Co. Has $6.70 Million Stock Position in AbbVie Inc. $ABBV

Pitcairn Co. cut its stake in shares of AbbVie Inc. (NYSE:ABBV) by 10.6% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 28,940 shares of the company’s stock after selling 3,417 shares during the period. AbbVie accounts for 0.5% of Pitcairn Co.’s holdings, making the stock its 29th largest position. Pitcairn Co.’s holdings in AbbVie were worth $6,701,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Evolution Wealth Management Inc. acquired a new position in AbbVie in the 2nd quarter valued at $26,000. Caitlin John LLC bought a new stake in shares of AbbVie in the third quarter valued at about $33,000. Spurstone Advisory Services LLC bought a new stake in shares of AbbVie in the second quarter valued at about $28,000. Redmont Wealth Advisors LLC acquired a new position in shares of AbbVie in the third quarter valued at about $41,000. Finally, Financial Gravity Companies Inc. bought a new position in AbbVie during the second quarter worth about $36,000. Institutional investors and hedge funds own 70.23% of the company’s stock.

AbbVie Stock Performance

Shares of ABBV opened at $232.07 on Friday. AbbVie Inc. has a 52-week low of $164.39 and a 52-week high of $244.81. The firm has a market cap of $410.34 billion, a price-to-earnings ratio of 98.33, a PEG ratio of 0.82 and a beta of 0.34. The business’s fifty day moving average is $224.72 and its 200-day moving average is $223.80.

AbbVie (NYSE:ABBV) last released its quarterly earnings data on Wednesday, February 4th. The company reported $2.71 earnings per share for the quarter, beating the consensus estimate of $2.65 by $0.06. AbbVie had a negative return on equity of 1,579.75% and a net margin of 6.91%.The business had revenue of $16.62 billion for the quarter, compared to analyst estimates of $16.39 billion. During the same period last year, the firm posted $2.16 earnings per share. AbbVie’s revenue was up 10.0% compared to the same quarter last year. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. As a group, research analysts forecast that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

AbbVie Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be given a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a yield of 3.0%. The ex-dividend date is Wednesday, April 15th. AbbVie’s dividend payout ratio is currently 293.22%.

Insider Transactions at AbbVie

In related news, EVP Perry C. Siatis sold 22,381 shares of the stock in a transaction that occurred on Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total value of $5,147,630.00. Following the completion of the transaction, the executive vice president owned 38,137 shares of the company’s stock, valued at $8,771,510. This represents a 36.98% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.25% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of analysts have issued reports on the stock. Wall Street Zen raised shares of AbbVie from a “buy” rating to a “strong-buy” rating in a report on Saturday, February 28th. UBS Group cut their price target on AbbVie from $240.00 to $230.00 and set a “neutral” rating for the company in a research note on Thursday, February 5th. Piper Sandler raised their price objective on AbbVie from $289.00 to $299.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 18th. Barclays assumed coverage on AbbVie in a report on Thursday, February 19th. They issued an “overweight” rating and a $275.00 price objective for the company. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of AbbVie in a report on Wednesday, January 21st. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and nine have issued a Hold rating to the company’s stock. According to MarketBeat.com, AbbVie has a consensus rating of “Moderate Buy” and a consensus target price of $253.15.

AbbVie News Roundup

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Positive Phase 3 AFFIRM results for risankizumab in moderately‑to‑severely active Crohn’s disease — higher clinical remission and endoscopic response vs. placebo, which could expand label/market for a high‑value asset and support longer‑term revenue growth. Assessing AbbVie (ABBV) Valuation After Positive Phase 3 Crohn’s Disease Trial Results
• Positive Sentiment: AbbVie advances venetoclax into a Phase 2 program for rare blood cancers in Japan — expands oncology pipeline and potential incremental revenue streams if studies read out positively. AbbVie Advances Venetoclax Into Rare Blood Cancers With New Phase 2 Study
• Positive Sentiment: Allergan Aesthetics (an AbbVie unit) highlights Medical Weight Loss data showing shifting patient demand — supports the aesthetics growth narrative and diversification beyond immunology. ALLERGAN AESTHETICS HIGHLIGHTS MEDICAL WEIGHT LOSS (MWL) DATA AND THE CHANGING PROFILE OF PATIENTS
• Positive Sentiment: Operationally constructive: AbbVie expansion reported to boost supply resilience for immunology medicines — lowers execution/supply risk for key franchises. AbbVie (NYSE:ABBV) Expansion Boosts Supply Resilience For Immunology Medicines
• Positive Sentiment: Third‑party bullish coverage and cash‑flow narratives emphasize AbbVie’s strong free cash flow and dividend profile — supportive for income investors and valuation stability. AbbVie: The Only Big Pharma Stock I’d Consider a Buy‑and‑Never‑Sell
• Neutral Sentiment: Corporate presentation/transcript from AbbVie at TD Cowen — may contain incremental detail on strategy and pipeline but no singular catalyst reported in the summary. AbbVie Inc. (ABBV) Presents at TD Cowen 46th Annual Health Care Conference Transcript
• Neutral Sentiment: Technical/market commentary notes the stock stabilizing near ~$233 while testing resistance levels — useful for short‑term traders but not a fundamental driver. AbbVie: Stabilizes Near $233 While Testing Resistance
• Neutral Sentiment: Market note reporting AbbVie’s share move relative to the broader market — descriptive of price action rather than a new driver. AbbVie (ABBV) Suffers a Larger Drop Than the General Market: Key Insights
• Negative Sentiment: Large senior notes offering (~$7.5–$8.0B) announced/completed — raises concerns about increased leverage and near‑term debt servicing; markets often view sizable debt raises as a near‑term negative for equity. AbbVie Completes $8 Billion Senior Notes Financing Offering AbbVie Announces $7.5 Billion Senior Notes Offering
• Negative Sentiment: AbbVie lost a bid to block Tennessee’s 340B law — regulatory/policy risk that could pressure pricing/reimbursements and is a negative for revenue in affected programs. AbbVie loses bid to block Tennessee 340B law

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.